A phase III randomized, double-blind, placebo-controlled study in participants with Myelofibrosis
We believe every cancer patient deserves the best chance to receive world-class healthcare options.
Contact Us What is Our Virtual Command Center?All cancer patients deserve equal access to the latest in cancer care therapies and treatments. Refer a patient, friend, family member or loved one to get in touch with Massive Bio.
Refer a PatientMassive Bio can improve your efficiency and patient satisfaction scores by pre-screening all cancer patients at your practice, at no cost to you. Patients are pre-screened with AI based technology for trials and advanced care options with sub-specialist and case management support.
Pre-screen PatientsJoin our growing network of key opinion leaders and oncologists. Your knowledge, research, and expertise in cancer treatment can make a difference.
Join Our Physician NetworkMulti-disciplinary background of experts like surgeons, radiation oncologists, pathologists, and medical oncologists gather to discuss treatment options for individual cancer patients.
Instant access to patient EMR lets trial sites receive lab results, radiology reports, and even X-ray images electronically while ensuring tests are not duplicated. Machine learning technology for scaled pre-screening; prescreening in the matter of seconds instead of hours. Submit patient records digitally to expedite the pre-screening for the Synergy-AI clinical trial matching process.
A phase III randomized, double-blind, placebo-controlled study in participants with Myelofibrosis
A phase III randomized, double-blind, placebo-controlled, multicenter study in patients with relapsed/refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
A phase III, randomized study for patients with Stage IV Adenocarcinoma of the Pancreas with no prior treatment for metastatic disease
A phase III, randomized study for patients with stage IV adenocarcinoma of the pancreas with no prior treatment for metastatic disease
A Phase I/II, open-label, multicenter study in patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer
A Phase II study in patients with Alteration/Biomarker-Positive Advanced or Metastatic Solid Tumors
A phase II, non-randomized clinical trial for patients with Metastatic Breast Cancers Harboring FGFR Amplifications
A phase II randomized study in women with Recurrent/Persistent/Metastatic Cervical Cancer who have progressed following first-line therapy
A phase III randomized, double-blind, placebo-controlled study in patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
A phase III randomized, double-blind study for the treatment of Newly Diagnosed Mantle Cell Lymphoma
A phase 1b/2a basket study in adult patients with Relapsed/Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
A first-in-human/phase I/II study for patients with Non-Small Cell Lung Cancer with MET Alteration